DOP2021000216A - Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona - Google Patents

Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona

Info

Publication number
DOP2021000216A
DOP2021000216A DO2021000216A DO2021000216A DOP2021000216A DO P2021000216 A DOP2021000216 A DO P2021000216A DO 2021000216 A DO2021000216 A DO 2021000216A DO 2021000216 A DO2021000216 A DO 2021000216A DO P2021000216 A DOP2021000216 A DO P2021000216A
Authority
DO
Dominican Republic
Prior art keywords
compounds
pyrrolo
pyridin
processes
formula
Prior art date
Application number
DO2021000216A
Other languages
English (en)
Spanish (es)
Inventor
Berger Markus
Schulze Volker
Bömer Ulf
Mönning Ursula
Sülzle Detlev
Schröder Jens
Niehues Michael
Meyerson Matthew
Siegel Stephan
Siegel Franziska
Graham Keith
Korr Daniel
Greulich Heidi
KAPLAN Bethany
Original Assignee
Bayer Ag
Broad Inst Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70456765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2021000216(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Broad Inst Inc, Dana Farber Cancer Inst Inc filed Critical Bayer Ag
Publication of DOP2021000216A publication Critical patent/DOP2021000216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DO2021000216A 2019-04-24 2021-10-22 Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona DOP2021000216A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US201962940036P 2019-11-25 2019-11-25
PCT/EP2020/061176 WO2020216781A1 (en) 2019-04-24 2020-04-22 4h-pyrrolo[3,2-c]pyridin-4-one compounds

Publications (1)

Publication Number Publication Date
DOP2021000216A true DOP2021000216A (es) 2022-05-15

Family

ID=70456765

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000216A DOP2021000216A (es) 2019-04-24 2021-10-22 Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona

Country Status (32)

Country Link
US (2) US12679836B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959211B1 (cg-RX-API-DMAC7.html)
JP (1) JP7641913B2 (cg-RX-API-DMAC7.html)
KR (1) KR102915019B1 (cg-RX-API-DMAC7.html)
CN (3) CN114127064B (cg-RX-API-DMAC7.html)
AU (1) AU2020262221B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019998B1 (cg-RX-API-DMAC7.html)
CA (1) CA3137218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210530A (cg-RX-API-DMAC7.html)
DK (1) DK3959211T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP21077614A (cg-RX-API-DMAC7.html)
ES (1) ES3068321T3 (cg-RX-API-DMAC7.html)
FI (1) FI3959211T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP202415804A (cg-RX-API-DMAC7.html)
HR (1) HRP20260409T1 (cg-RX-API-DMAC7.html)
IL (1) IL287390B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210285A1 (cg-RX-API-DMAC7.html)
LT (1) LT3959211T (cg-RX-API-DMAC7.html)
MA (1) MA55751B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012987A (cg-RX-API-DMAC7.html)
PE (1) PE20220254A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552693A1 (cg-RX-API-DMAC7.html)
PL (1) PL3959211T3 (cg-RX-API-DMAC7.html)
PT (1) PT3959211T (cg-RX-API-DMAC7.html)
RS (1) RS68081B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111304UA (cg-RX-API-DMAC7.html)
TW (1) TWI849114B (cg-RX-API-DMAC7.html)
UA (1) UA130453C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020216781A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
MX2023003362A (es) * 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
EP4244225B1 (en) * 2020-11-11 2026-06-03 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法
IL315739A (en) * 2022-03-24 2024-11-01 Scorpion Therapeutics Inc Methods of synthesizing egfr inhibitors
WO2023205595A2 (en) * 2022-04-20 2023-10-26 Celyn Therapeutics, Inc Egfr inhibitors in cancer treatment
CA3270236A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation
CA3270230A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Crystalline forms of her2/mutegfr inhibitors and process for their preparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
JP2008291023A (ja) 2007-04-27 2008-12-04 Sumitomo Chemical Co Ltd アミド化合物とその用途
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
ES2722431T3 (es) 2014-12-08 2019-08-12 Bayer Pharma AG Novedosos compuestos de aril-cianoguanidina
WO2016100166A1 (en) 2014-12-15 2016-06-23 Bristol-Myers Squibb Company SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
CN107406417B (zh) * 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
US20250136599A1 (en) 2025-05-01
CL2021002770A1 (es) 2022-05-27
RS68081B1 (sr) 2026-05-29
DK3959211T3 (da) 2026-04-27
AU2020262221B2 (en) 2025-11-20
CN117946100A (zh) 2024-04-30
JP2022532850A (ja) 2022-07-20
ES3068321T3 (en) 2026-05-29
CN114127064A (zh) 2022-03-01
MA55751B1 (fr) 2026-04-30
CO2021014022A2 (es) 2022-03-29
WO2020216781A1 (en) 2020-10-29
IL287390B1 (en) 2025-07-01
BR112021019998A2 (cg-RX-API-DMAC7.html) 2021-12-07
UA130453C2 (uk) 2026-02-25
MX2021012987A (es) 2022-04-01
ECSP21077614A (es) 2021-11-30
CA3137218A1 (en) 2020-10-29
TWI849114B (zh) 2024-07-21
BR112021019998B1 (pt) 2024-01-16
CN114127064B (zh) 2023-12-26
HRP20260409T1 (hr) 2026-06-05
PE20220254A1 (es) 2022-02-16
EP3959211B1 (en) 2026-02-18
KR20220004103A (ko) 2022-01-11
JOP20210285A1 (ar) 2023-01-30
PT3959211T (pt) 2026-04-23
MA55751A (fr) 2022-03-02
LT3959211T (lt) 2026-06-10
FI3959211T3 (fi) 2026-04-01
CR20210530A (es) 2021-12-23
PH12021552693A1 (en) 2022-03-21
TW202106683A (zh) 2021-02-16
GEAP202415804A (en) 2024-02-12
IL287390A (en) 2021-12-01
CN117986251A (zh) 2024-05-07
AU2020262221A1 (en) 2021-11-18
GEP20247648B (en) 2024-07-25
KR102915019B1 (ko) 2026-01-21
PL3959211T3 (pl) 2026-07-27
US12679836B2 (en) 2026-07-14
US20220298157A1 (en) 2022-09-22
JP7641913B2 (ja) 2025-03-07
IL287390B2 (en) 2025-11-01
SG11202111304UA (en) 2021-11-29
EP3959211A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
CO2021014022A2 (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
BR112017016193A2 (pt) derivados de 4h-pirrolo[3,2-c]piridin-4-ona
IL285311A (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
MX372760B (es) Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorficas y metodos de uso de los mismos.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2023000894A1 (es) Compuestos de heteroarilo fusionados y su uso como inhibidores de camkii
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
MX392601B (es) Análogos sintéticos de las ecteinascidinas y su uso como agentes antitumorales.
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
MY187449A (en) New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
MX373652B (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2022000492A1 (es) Proceso para la preparación de estetrol de alta pureza.
MX2015011438A (es) Procedimiento para preparar compuestos benzoxazepina.
CR8358A (es) Pentalones transpuestos, un metodo para prepararlos y su uso como antiinflamatorios
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
PH12018502733A1 (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
MX2024010216A (es) Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación
PY2265946A (es) Nueva (3-quinolil)-quinazolina
CL2024003050A1 (es) Método e intermediario para la preparación de apalutamida.
UY29481A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como antiinflamatorios.
EA202192881A1 (ru) 4Н-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ
MX2021001581A (es) Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.